These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36756815)

  • 1. Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study.
    Xu H; Zheng J; Zhao X; Zhou Q; Fan B; Wu H; Zhang S; Ge J
    Cardiovasc Res; 2023 Jun; 119(6):1352-1360. PubMed ID: 36756815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
    Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No association between SARS-CoV-2 vaccination and ischaemic stroke or high-risk transient ischaemic attack.
    Komarek S; Dejakum B; Moelgg K; Boehme C; Karisik A; Toell T; Kiechl S; Knoflach M; Pechlaner R; Mayer-Suess L
    J Neurol Sci; 2024 Jan; 456():120834. PubMed ID: 38134562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.
    Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Lancet Microbe; 2022 Dec; 3(12):e944-e955. PubMed ID: 36375482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of inactivated SARS-CoV-2 vaccination on embryo ploidy: a retrospective cohort study of 133 PGT-A cycles in China.
    Huang J; Xia L; Tian L; Fan H; Xu D; Ai X; Wu X; Chen J; Xing G; Huang L; Zuo H; Chen J; Li M; Zhang K; Liu P; Lin J; Wu Q
    Biol Res; 2022 Aug; 55(1):26. PubMed ID: 35962402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CoronaVac and BBIBP-CorV vaccines against SARS-CoV-2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study.
    Hu Z; Jin Z; Zhou M; Zhang C; Bao Y; Gao X; Wang G
    J Med Virol; 2023 Oct; 95(10):e29143. PubMed ID: 37814963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study.
    Chen Z; Tang W; Feng N; Lv M; Meng F; Wu H; Zhao Y; Xu H; Dai Y; Xue J; Wang J; Xu A; Zhang B; Chu D; Li Y; Wu D; Dong L; Zhang S; Xue R
    EBioMedicine; 2024 Jan; 99():104912. PubMed ID: 38096688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.
    Cao Z; Zhang C; Zhao S; Sheng Z; Xiang X; Li R; Qian Z; Wang Y; Chen B; Li Z; Liu Y; An B; Zhou H; Cai W; Wang H; Gui H; Xin H; Xie Q
    Infect Dis Poverty; 2022 May; 11(1):56. PubMed ID: 35578350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease.
    Hong X; Pan H; Su Y; Hu Q; Sun Y; Liu H; Cheng X; Ye J; Shi H; Meng J; Zhou Z; Jia J; Liu T; Wang M; Chen X; Ma Y; Tang Z; Wang F; Zhang H; You Y; Zhu D; Chen L; Yang C; Teng J; Chi H
    Rheumatology (Oxford); 2023 Jun; 62(6):2262-2266. PubMed ID: 36282541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
    Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.